Skip to main content
Smart Investors Daily
CL

NASDAQ · CLLS

Cellectis S.A.

Healthcare · Biotechnology

$1.26

Up+$0.01 (+0.80%)

Updated Oct 10, 2026, 4:16 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
523.7M
P/E ratio
-8.66
Dividend yield
0.00%
52-week range
$1.22 – $4.55
Volume
75.76K
Avg. volume
146.61K

Price performance · CLLS

CLLS price history

1M range · 0 trading sessions · Daily adjusted prices

CLLS does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CLLS news

The latest Smart Investors Daily articles mentioning CLLS.

CLLS research

Overview

Company profile and research snapshot.

Company profile

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
CLLS recent ratings
DateFirmRatingTarget
Sep 15, 2026ODDO BHFBuy—
Sep 14, 2026JEFFERIESBuy—
Aug 12, 2026CITIZENSOutperform—
Jul 8, 2026ODDO BHFBuy—
Jul 7, 2026ODDO BHFBuy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.